Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
23 hedge funds and large institutions have $89M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
21% more funds holding
Funds holding: 19 → 23 (+4)
8% more capital invested
Capital invested by funds: $82.5M → $89M (+$6.49M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$6.42M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.62M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$3.72M |
| 4 |
O
OrbiMed
New York
|
+$1.93M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.69M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.51M |
| 3 |
JPC
Jackson Park Capital
Alpine,
Utah
|
-$185K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$118K |
| 5 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$35K |
NBRV Hedge Fund Activity: Q4 2016 in Review
23 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2016, worth a combined $89M — up 7.9% from $82.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NBRV positions and 3 closed out — a net gain of 4 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Novo Holdings A/S, adding an estimated $6.42M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.69M sold.
- 23 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2016, up from 19 in Q3 2016.
- Funds reported $89M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2016, up 7.9% quarter-over-quarter.
- 7 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2016 and 3 closed out, a net change of +4 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2016 was Novo Holdings A/S, an estimated $6.42M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2016 was Opaleye Management, an estimated $1.69M sold.
Based on aggregated 13F filings for Q4 2016.